secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alto Neuroscience, Inc. (ANRO)
CIK:        0001999480
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001999480-25-000075
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alto Neuroscience Q2 net loss $17.7M; ALTO-207 acquisition expands TRD pipeline; data readouts ahead
--------------------------------------------------------------------------------

- Net loss $17.7M in Q2 2025 vs $16.0M in Q2 2024; cash $148.1M expected to fund operations into 2028.
- Acquired ALTO-207 (pramipexole/ondansetron) from Chase; Phase 2b in TRD planned by mid-2026.
- ALTO-101 Phase 2 POC topline data for CIAS expected 2H 2025; ALTO-300 Phase 2b MDD data mid-2026.
- ALTO-100 Phase 2b bipolar depression data expected 2H 2026; ALTO-203 showed positive pharmacodynamic results.
- Appointed Raymond Sanchez, M.D., to Board; class structure reconstituted, committee assignments updated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1999480/000199948025000075/0001999480-25-000075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1999480/000199948025000075/alto-20250812.htm
  HTML page:      https://secwatch.observer/filing/0001999480-25-000075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer